Fundraising FoxCobro Ventures
Venture capitalMclean · Seed–Series A · 3 people tracked
Find your way into Cobro Ventures
Each arrow is one introduction. Sign up to fill in the first one.
Ask Hieu Bui to introduce you to Todd Kaloudis
You →Hieu · together at Platform Science →Todd
Ask Jamie Chen to introduce you to Marc Cohen
You →Jamie · together at ONCoPEP →Marc
Ask Sam Okafor to introduce you to Alain J. Cohen
You →Sam · together at C4 Therapeutics →Alain
Sign up to find every way you can get introduced to Cobro Ventures
- Your email: who you already know at Cobro Ventures, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Cobro Ventures team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
Cobro Ventures invests in technology and biotech businesses, drawing on a 25+ year track record as founders, operators, and investors with multiple exits through IPO and M&A. Launched by the entrepreneurs behind OPNET Technologies, the firm embraces a 'doing well by doing good' philosophy. It seeks high-impact opportunities, backs world-class scientific and technology experts, and leverages its experience with intellectual property and strategic business development to build significant value.
Source: firm website, verified Sep 29, 2026.
Team · 3 people
from public directoriesFounder mafia
2 people who came through Cobro Ventures went on to found or lead other companies.
What they invest in
from 6 of 7 portfolio companiesBiotech ×6AI & Machine Learning ×1Deep Tech ×1Hardware ×1Medical Devices ×1
HQs:United States×6
Investments · 7 tracked
founders shown can be your intro pathBy year:2023 · 12022 · 42018 · 12015 · 17 dated
C4 Therapeutics develops targeted protein degradation medicines aimed at treating disease.
BiotechCambridge, US
Kenneth C. Anderson(Director)Andrew J. Hirsch(Director and Chief Executive Officer)in
BoardMarc Cohen(Executive Officer, Director)inJason Fisherman(Executive Officer, Director)Miles Stuchin(Director)Bruce Downey(Director)
Co-investors3E Bioventures CapitalBain Capital Life SciencesNextech InvestRA Capital
AI Proteins designs engineered miniproteins for drug discovery and development in the biopharmaceutical industry.
AI & Machine LearningBiotechDeep TechAndover, US
Chris Bahl(Executive Officer, Director)inDominique Verhelle(Director)Bill McKee(Director)Julia Novina(Executive Officer)Marc A. Cohen(Executive Officer, Director)inGeoff Meyerson(Director)
Board seatTodd Kaloudis· per SEC Form D
Co-investorsMission BiocapitalTachyon Ventures
Windgap Medical designs autoinjector devices for delivering complex drugs and combination products, including systems for reconstituting lyophilized or powdered compounds, sequential delivery of two liquid therapies, high-viscosity medications, and large-volume injections.
BiotechHardwareMedical DevicesWatertown, US
Brent Buchine(Director)inMax Meehan(Executive Officer)inAaron Mann(Executive Officer, Director)inJason Durkin(Executive Officer)inJohn Cadigan(Executive Officer)inAnthony Watson(Executive Officer)in
Co-investorsBantam GroupBoston Harbor AngelsColle Capital PartnersLaunchpad Venture GroupTaiwania Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Microbial Machines, Inc.NextRNA TherapeuticsMana TherapeuticsRegenacy Pharmaceuticals
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 1
1 IPOsC4 TherapeuticsNASDAQ: CCCC
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| C4 Therapeutics | 5.2% | $37.00 | Jun 2021 | $91.9M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Cobro Ventures made?
- Cobro Ventures has 7 tracked investments, 1 of which have exited.
- What stage does Cobro Ventures invest at?
- Cobro Ventures invests at the Seed, Series A stages.
- What sectors does Cobro Ventures focus on?
- Cobro Ventures focuses on AI & Machine Learning, Biotech, Deep Tech, Enterprise Software, SaaS.
- Where is Cobro Ventures located?
- Cobro Ventures is headquartered in Mclean, US.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
Fly Ventures is an early-stage venture firm that backs founders at the zero-to-one stage, with portfolio companies going on to raise substantial follow-on funding from top US and European VCs.